Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Appointed director
CC transcript
Inv. presentation
Director departure
|
|
INTERPACE BIOSCIENCES, INC. (IDXG)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
8-K
| Quarterly results |
| 03/27/2023 |
8-K
| Quarterly results |
| 11/15/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/04/2022 |
8-K
| Quarterly results |
| 10/04/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/07/2022 |
8-K
| Acquisition/merger/asset purchase announced|
Docs:
|
"Execution Version",
"Execution Version",
"Unaudited Pro Forma Condensed Consolidated Financial Information The unaudited pro forma condensed consolidated financial statements were prepared to assist readers in understanding the nature and effects of the sale by Interpace Biosciences, Inc., , on August 31, 2022 of substantially all of the assets and the ongoing business comprising the Company’ s Pharma Services business pursuant to the Asset Purchase Agreement, dated as of August 31, 2022, by and among Flagship Biosciences, Inc. , Interpace Pharma Solutions, Inc. and the Company . The unaudited pro forma condensed consolidated statements of operations for the six months ended June 30, 2022, and for the year ended December 31, 2021 have been prepared with the assumption that the Asset Sale was completed as of January 1, 2021. The Un..." |
|
| 08/15/2022 |
8-K
| Quarterly results |
| 05/16/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 04/14/2022 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 03/31/2022 |
8-K
| Quarterly results|
Docs:
|
"INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Years Ended December 31, December 31, 2021 2020 2021 2020 Revenue, net $ 10,853 $ 9,646 $ 41,314 $ 32,398 Cost of revenue 6,404 6,517 23,369 21,673 Gross Profit 4,449 3,129 17,945 10,725 Sales and marketing 2,482 2,478 10,067 9,254 Research and development 407 673 1,882 2,795 General and administrative 4,030 5,508 13,669 18,192 Transition expenses 111 1,780 2,585 2,578 Loss on DiamiR transaction 248 - 13 - Acquisition amortization expense 728 1,115 4,064 4,461 Change in fair value of contingent consideration Total operating expenses 7,725 11,065 31,942 36,791 Operating loss Interest accretion expense Related party interest - - Other income, net 467 Loss from continuing operations before ta..." |
|
| 01/28/2022 |
8-K
| Quarterly results |
| 01/27/2022 |
8-K
| Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of... |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"INTERPACE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 Revenue, net $ 9,472 $ 8,248 $ 30,461 $ 22,752 Cost of revenue 5,848 5,194 16,965 15,156 Gross Profit 3,624 3,054 13,496 7,596 Sales and marketing 2,456 2,699 7,585 6,776 Research and development 416 763 1,475 2,123 General and administrative 3,278 3,795 9,582 12,683 Transition expenses 363 687 2,474 798 Gain on DiamiR transaction - - - Acquisition amortization expense 1,112 1,115 3,336 3,346 Total operating expenses 7,625 9,059 24,217 25,726 Operating loss Interest accretion expense Related party interest - - Other income , net 45 473 Loss from continuing operations before tax provision for income taxes 14 43 Loss from cont..." |
|
| 11/09/2021 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 11/02/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"[Signature page follows.] - 24 - IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as of the Effective Date. BORROWER: INTERPACE BIOSCIENCES, INC. By: Name: Thomas W. Burnell Title: President INTERPACE DIAGNOSTICS CORPORATION By: Name: Thomas W. Burnell Title: President INTERPACE DIAGNOSTICS, LLC By: Name: Thomas W. Burnell Title: President INTERPACE PHARMA SOLUTIONS, INC. By: Name: Thomas W. Burnell Title: President LENDER: BROADOAK FUND V, L.P. By Name: William Snider Title: Manager [Signature page to Loan and Security Agreement] EXHIBIT A – COLLATERAL DESCRIPTION The Collateral consists of all of Borrower’ s right, title and interest in and to the following personal property: All goods, Accounts , Equipment, Inventory, contract rights or rights to payment ...",
"FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT AND CONSENT This First Amendment to Loan and Security Agreement and Consent is entered into as of November 1, 2021 between Interpace Biosciences, Inc., a Delaware corporation , Interpace Diagnostics Corporation, a Delaware corporation , Interpace Diagnostics, LLC, a Delaware limited liability company and Interpace Pharma Solutions, Inc., a Delaware corporation and Comerica Bank . RECITALS Borrowers and Bank are parties to that Loan and Security Agreement dated October 13, 2021, as it may be amended, restated or otherwise modified from time to time . The parties desire to amend the Agreement in accordance with the terms of this Amendment. In addition, Borrowers have requested Bank’ s consent to the incurrence of certain Indebtedness and the pre...",
"Recitals",
"Interpace Biosciences Announces New $8 Million Term Loan with BroadOak Capital Partners and Repayment of Private Equity Loans PARSIPPANY, NJ, November 2, 2021 — Interpace Biosciences, Inc. today announced that it, along with its subsidiaries, has entered into a new $8 million term loan with BroadOak Fund V, L.P. . The proceeds of the BroadOak Loan were used primarily to repay principal and interest on the $7.5 million short-term promissory notes due to the Company’ s two private equity stockholders, Ampersand 2018 Limited Partnership and 1315 Capital II, L.P. . The BroadOak Loan was designed to extend the Company’ s debt structure and increase operating flexibility. In combination with the recently announced $7.5 million revolving credit facility with Comerica Bank, the Company believes i..." |
|
| 10/18/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"INTERPACE BIOSCIENCES, INC. INTERPACE DIAGNOSTICS CORPORATION INTERPACE DIAGNOSTICS, LLC INTERPACE PHARMA SOLUTIONS, INC. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT is entered into as of October 13, 2021, by and between Comerica Bank, a Texas banking association , Interpace Biosciences, Inc., a Delaware corporation , Interpace Diagnostics Corporation, a Delaware corporation , Interpace Diagnostics, LLC, a Delaware limited liability company and Interpace Pharma Solutions, Inc., a Delaware corporation RECITALS A. Borrowers wish to obtain credit from time to time from Bank, and Bank desires to extend credit to Borrowers. B. This Agreement sets forth the terms on which Bank will advance credit to Borrowers, and Borrowers will repay the amounts owing to Bank. AGREEMENT The par...",
"SUBORDINATION AGREEMENT",
"About Interpace Biosciences" |
|
| 10/01/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Amendment”) is made and entered into as of September 29, 2021 by and between Interpace Biosciences, Inc., a Delaware corporation , and Ampersand 2018 Limited Partnership, a Delaware limited partnership . Capitalized terms used herein but not otherwise defined shall have the respective meanings given to them in the Note . WHEREAS, the Borrower has entered into that certain Secured Promissory Note dated as of January 7, 2021 , made in favor of the Noteholder, in the aggregate principal amount of $3,000,000.00",
"Amendment”) is made and entered into as of September 29, 2021 by and between Interpace Biosciences, Inc., a Delaware corporation , and 1315 Capital II, L.P., a Delaware limited partnership (the “Noteholder" |
|
| 08/31/2021 |
8-K
| Quarterly results |
| 08/10/2021 |
8-K
| Quarterly results |
| 08/06/2021 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 |
| 06/29/2021 |
8-K
| Quarterly results |
| 05/11/2021 |
8-K
| Quarterly results |
| 04/05/2021 |
8-K
| Quarterly results |
| 02/24/2021 |
8-K
| Quarterly results |
| 02/17/2021 |
8-K
| Quarterly results |
| 02/04/2021 |
8-K
| Quarterly results |
| 01/20/2021 |
8-K
| Quarterly results |
| 01/11/2021 |
8-K
| Quarterly results |
| 11/25/2020 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/19/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure... |
|
|
|